FINAL DIAGNOSIS: PART 1: BREAST, LEFT, SEGMENTAL MASTECTOMY -INFILTRATING DUCTAL CARCINOMA, NOS TYPE, MODERATELY DIFFERENTIATED. THE TUMOR MEASURES 2.5 CM (GROSS MEASUREMENT), NOTTINGHAM SCORE 6/9 (TUBULE 2, NUCLEAR GRADE 2, MITOSIS 2; OVERALL GRADE 2/3). C. NO LYMPHOVASCULAR INVASION IS IDENTIFIED. D. DUCTAL CARCINOMA IN-SITU, SOLID AND CRIBRIFORM SUBTYPES, NUCLEAR GRADE 2, COMPRISES 25% OF THE TOTAL TUMOR VOLUME AND IS PRESENT IN ASSOCIATION WITH INVASIVE CARCINOMA. E. MARGINS: ALL MARGINS OF RESECTION ARE FREE OF IN-SITU OR INVASIVE CARCINOMA. THE CLOSEST POSTERIOR MARGIN IS 1 MM AWAY (SLIDE 1B). FIBROCYSTIC CHANGES, DUCTAL EPITHELIAL HYPERPLASIA, COLUMNAR CELL HYPERPLASIA, ATYPICAL DUCTAL HYPERPLASIA, SCLEROSING ADENOSIS, AND PREVIOUS BIOPSY SITE CHANGES. G. ESTROGEN RECEPTOR POSITIVE, PROGESTERONE RECEPTOR POSITIVE, HER-2/NEU NEGATIVE (IHC SCORE 1+), CROSS REFER PART 2: BREAST, LEFT, LATERAL MARGIN, EXCISION -A. NO IN-SITU OR INVASIVE CARCINOMA IDENTIFIED. B. FIBROCYSTIC CHANGES, DUCTAL EPITHELIAL HYPERPLASIA, SCLEROSING ADENOSIS, AND PART 3: SENTINEL LYMPH NODE #1, LEFT AXILLA, BIOPSY -ONE BENIGN LYMPH NODE, NO TUMOR SEEN (0/1). PART 4: SENTINEL LYMPH NODE #2, LEFT AXILLA, BIUPSY -ONE OUT OF TWO LYMPH NODES POSITIVE FOR METASTATIC CARCINOMA (1/2), THE METASTATIC FOCUS MEASURES 1 CM (ON GLASS SLIDE). EXTRACAPSULAR EXTENSION IS IDENTIFIED. 105-0-3 Carcinoma, infiltrating ductil, NOS 8500/3 Site: breast, NOS C50.9 3/13/11 for PART 5: SENTINEL LYMPH NODE #3, LEFT AXILLA, BIOPSY -TWO BENIGN LYMPH NODES, NO TUMOR SEEN (0/2). CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST LATERALITY: Left PROCEDURE: Segmental LOCATION: Not specified SIZE OF TUMOR: Maximum dimension invasive component: 2.5 cm **MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI:** No **TUMOR TYPE (invasive component):** Ductal adenocarcinoma, NOS NOTTINGHAM SCORE: Nuclear grade: 2 Tubule formation: 2 UUID: A3CDF051-4162-47EC-BE8A-1519A5564518 Mitotic activity score: 2 TCGA-BH-AOBJ-01A-PR Redacted Total Nottingham score: 6 Nottingham grade (1, 2, 3): 2 ANGIOLYMPHATIC INVASION: No **DERMAL LYMPHATIC INVASION:** No **CALCIFICATION:** No **TUMOR TYPE, IN SITU:** Cribriform Solid DCIS admixed with invasive carcinoma Percent of tumor occupied by in situ component: 25 % SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: No Distance of invasive tumor to closest margin: 1 mm SURG MARGINS INVOLVED BY IN SITU COMPONENT: Distance of in situ disease to closest margin: 1 mm **PAGET'S DISEASE OF NIPPLE:** No LYMPH NODES POSITIVE: 1 riteria LYMPH NODES EXAMINED: 5 Diagnosis Discrepancy Primary Tumor Site Discrepancy METHOD(S) OF LYMPH NODE EXAMINATION: IIPAA Discrepancy H/E stain Prior Malignancy History SENTINEL NODE METASTASIS: Dual/Synchronous Primary Yes **ONLY KERATIN POSITIVE CELLS ARE PRESENT:** SIZE OF NODAL METASTASES: Diameter of largest lymph node metasiasis: 10 mm LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: Yes METASTASES TO IPSILATERAL INTERNAL MAMMARY LYMPH NODE (IF APPLICABLE): No

SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST TISSUE: ADH. FCD pT2 T STAGE, PATHOLOGIC: N STAGE, PATHOLOGIC: pN1 MI STACE DATHOLOGIC. MAY

No